AI collaboration to optimise development of cancer inhibitor drug
Lantern Pharma has entered a strategic AI-driven collaboration with French biotechnology company Oregon Therapeutics to optimise the development of its first-in-class protein disulfide isomerase (PDI)1 inhibitor drug candidate XCE853 in novel and targeted cancer indications. Lantern will be leveraging its RADR AI platform to uncover biomarkers and… Read More